Physician profile
Steven Chen
NPI 1649358813
$5,799.69
in general payments reported to CMS, 2019-2025
36 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $635 · 2021: $193 · 2022: $1,306 · 2023: $827 · 2024: $864 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $818.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $647.81 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $630.55 | 2019-2020 | |
| Lilly USA, LLC | $609.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $433.46 | 2019-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $297.75 | 2019-2025 | Repatha, Otezla, Otezla |
| Corcept Therapeutics | $273.59 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.53 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.43 | 2022-2023 | |
| Pfizer INC. | $207.86 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.91 | 2019-2025 | Jardiance |
| Daiichi Sankyo INC. | $122.48 | 2023-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $100.85 | 2019-2025 | Gardasil 9, Capvaxive, Rotateq |
| Phadia US INC. | $93.46 | 2022-2023 | Immunocap |
| Vanda Pharmaceuticals INC. | $76.13 | 2020-2023 | Hetlioz |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.